<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115938">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01839968</url>
  </required_header>
  <id_info>
    <org_study_id>11-117</org_study_id>
    <nct_id>NCT01839968</nct_id>
  </id_info>
  <brief_title>Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to
      reverse the antiplatelet effects of prasugrel.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Platelet reactivity assessed by light transmittance aggregometry (LTA) after ex-vivo normal platelet addition</measure>
    <time_frame>within the first 6-24 hours after antiplatelet drug loading dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Acquired Platelet Disorder</condition>
  <arm_group>
    <arm_group_label>Study patients</arm_group_label>
    <description>Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma</intervention_name>
    <arm_group_label>Study patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute coronary syndrome who received a loading dose of prasugrel within 6
        and 24h.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute coronary syndrome

          -  Prasugrel loading dose 6-24h before inclusion

        Exclusion Criteria:

          -  Clopidogrel loading dose

          -  GPIIbIIIa use within 10 days before inclusion

          -  Known congenital thrombopathy and/or congenital coagulation defect
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fanny Bonhomme, MD</last_name>
    <phone>+41795532175</phone>
    <email>fanny.bonhomme@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Geneva</name>
      <address>
        <city>Geneva</city>
        <state>GE</state>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanny Bonhomme, MD</last_name>
      <phone>+41795532175</phone>
      <email>fanny.bonhomme@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Fanny Bonhomme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 24, 2013</lastchanged_date>
  <firstreceived_date>April 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Fanny Bonhomme</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blood Platelet Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prasugrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
